Streetbeat News

Regulatory

EGRX

NDAQ

Eagle Pharmaceuticals, Inc. has announced its intention to delist from the Nasdaq Global Market and deregister with the SEC. The company will file a Form 25 to remove its listing, following a previously disclosed plan.

Portfolio Pulse from

November 15, 2024 | 10:15 pm

LUNA

NDAQ

Luna Innovations has received a notice from Nasdaq due to a delay in filing its Q3 2024 Form 10-Q, which could impact its stock listing status.

Portfolio Pulse from

November 15, 2024 | 10:00 pm

NVNI

Nvni Group Limited has received a delisting notice from Nasdaq due to non-compliance with listing rules, specifically for failing to file its 2023 Annual Report.

Portfolio Pulse from

November 15, 2024 | 9:45 pm

LUXH

NDAQ

LuxUrban Hotels Inc. (Nasdaq: LUXH) announced a one-for-seventy reverse stock split to regain Nasdaq compliance.

Portfolio Pulse from

November 15, 2024 | 9:45 pm

F

Ford has been ordered to pay $165 million due to delays in rearview camera recalls, marking the NHTSA's second-largest fine ever. Ford is required to review all recalls from the past three years and potentially file new ones.

Portfolio Pulse from

November 15, 2024 | 9:15 pm

IVA

Inventiva will present final data from a Phase 2 study on lanifibranor combined with empagliflozin for MASH and T2D at the AASLD Liver Meeting.

Portfolio Pulse from

November 15, 2024 | 9:15 pm

TAK

Masa Takeda, portfolio manager at Hennessy Japan Fund, discusses his positive outlook on Japanese stocks and the potential impact of President-elect Trump's proposed tariffs on Japanese companies.

Portfolio Pulse from

November 15, 2024 | 9:00 pm

QQQ

Federal Reserve Chair Jerome Powell's hawkish stance has caused a downturn in the stock market. However, indicators such as the QQQ chart, market sentiment, and seasonality suggest that the decline may be limited.

Portfolio Pulse from

November 15, 2024 | 8:30 pm

IMMP

Immutep's eftilagimod alpha shows promise in treating non-squamous NSCLC patients when combined with KEYTRUDA and chemotherapy, based on positive phase 1 INSIGHT-003 study results. Further data is expected in 2025, with a phase 3 study planned.

Portfolio Pulse from

November 15, 2024 | 8:30 pm

JAGX

Jaguar Health, Inc. (JAGX) held its Q3 2024 earnings call, discussing growth prospects, market acceptance, and competitive challenges. The company highlighted forward-looking statements subject to risks and uncertainties.

Portfolio Pulse from

November 15, 2024 | 8:00 pm